The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.

The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies ...

The Federal Trade Commission said the three companies' practices have artificially inflated list prices for insulin.

Three companies that process about 80% of prescriptions in the United States — Caremark, Express Scripts and OptumRx — have ...

The three price benefit managers jointly administer 80% of all prescriptions in the U.S., the FTC said in the lawsuit.

On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers ...

The Federal Trade Commission Friday announced it was suing the country's three biggest pharmacy benefit managers, claiming ...

The federal government has initiated a lawsuit against leading Pharmacy Benefit Managers (PBMs) — Caremark, Express Scripts, and OptumRx — accusing them of anticompetitive practices that have driven ...

But two notable investigations — one still active — show the Federal Trade Commission (FTC ... PBMs (including related to the price of insulin), 45 it is the legislative arena that seems ...

According to her plan, new penalties enforced by the Federal Trade Commission and other agencies ... She also wants to limit the price of insulin payments to US$35 per month, increase subsidies ...

According to her plan, new penalties enforced by the Federal Trade Commission and other agencies would be imposed ... She also wants to limit the price of insulin payments to US$35 per month, increase ...